Improved antitumor response to isolated limb perfusion with tumor necrosis factor after upregulation of endothelial monocyte-activating polypeptide II in soft tissue sarcoma

Annals of Surgical Oncology

Volumn 9, Issue 8, 2002, Pages 812-819

  Lans, T E ^a   Hagen, T L M Ten ^a   Van Horssen, R ^a   Wu, P C ^b   Van Tiel, S T ^a   Libutti, S K ^b   Alexander, H R ^b   Eggermont, A M M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

EMAP II; Limb perfusion; Sarcoma; TNF

Indexed keywords

ENDOTHELIAL MONOCYTE ACTIVATING POLYPEPTIDE II; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; GENETIC TRANSFECTION; IMMUNOHISTOCHEMISTRY; LIMB PERFUSION; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; SOFT TISSUE SARCOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; CYTOKINES; DISEASE MODELS, ANIMAL; EXTREMITIES; MALE; NEOPLASM PROTEINS; RATS; RATS, INBRED BN; RNA-BINDING PROTEINS; SARCOMA; SOFT TISSUE NEOPLASMS; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036789833     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1245/ASO.2001.09.019     Document Type: Article

References (18)

1. Asher A, Mule JJ, Reichert CM, Shiloni E, Rosenberg SA. Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol 1987;138:963-74.
2. Lienard D, Eggermont AM, Koops HS, et al. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. Melanoma Res 1999;9:491-502.
3. Vaglini M, Belli F, Ammatuna M, et al. Treatment of primary or relapsing limb cancer by isolation perfusion with high-dose alphatumor necrosis factor, gamma-interferon, and melphalan. Cancer 1994;73:483-92.
4. Eggermont AM, Schraffordt KH, Lienard D, et al. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 1996;14:2653-65.
5. Berger AC, Alexander HR, Wu PC, et al. Tumor necrosis factor receptor I (p55) is upregulated on endothelial cells by exposure to the tumor-derived cytokine endothelial monocyte-activating polypeptide II (EMAP-II). Cytokine 2000;12:992-1000.
6. de Wilt JH, Manusama ER, van Tiel ST, van Ijken MG, ten Hagen TL, Eggermont AM. Prerequisites for effective isolated limb perfusion using tumor necrosis factor alpha and melphalan in rats. Br J Cancer 1999;80:161-6.
7. Manusama ER, Stavast J, Durante NM, Marquet RL, Eggermont AM. Isolated limb perfusion with TNF alpha and melphalan in a rat osteosarcoma model: a new anti-tumor approach. Eur J Surg Oncol 1996;22:152-7.
8. Wu PC, Alexander HR, Huang J, et al. In vivo sensitivity of human melanoma to tumor necrosis factor (TNF)-alpha is determined by tumor production of the novel cytokine endothelial-monocyte activating polypeptide II (EMAPII). Cancer Res 1999;59:205-12.
9. Nooijen PT, Manusama ER, Eggermont AM. et al. Synergistic effects of TNF-alpha and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study. Br J Cancer 1996;74:1908-15.
10. Benckhuijsen C, Varossieau FJ, Hart AA, Wieberdink J, Noordhoek J. Pharmacokinetics of melphalan in isolated perfusion of the limbs. J Pharmacol Exp Ther 1986;237:583-8.
11. Olieman AF, Lienard D, Eggermont AM, et al. Hyperthermic isolated limb perfusion with tumor necrosis factor alpha, interferon gamma, and melphalan for locally advanced nonmelanoma skin tumors of the extremities: a multicenter study. Arch Surg 1999; 134:303-7.
12. Berger AC, Alexander HR, Tang G, et al. Endothelial monocyte activating polypeptide II induces endothelial cell apoptosis and may inhibit tumor angiogenesis. Microvasc Res 2000;60:70-80.
13. Murray JC, Barnett G, Tas M, et al. Immunohistochemical analysis of endothelial-monocyte-activating polypeptide-II expression in vivo. Am J Pathol 2000;157:2045-53.
14. Kao J, Ryan J, Brett G, et al. Endothelial monocyte-activating polypeptide II. A novel tumor-derived polypeptide that activates host-response mechanisms. J Biol Chem 1992;267:20239-47.
15. Marvin MR, Libutti SK, Kayton M, et al. A novel tumor-derived mediator that sensitizes cytokine-resistant tumors to tumor necrosis factor. J Surg Res 1996;63:248-55.
16. de Roos WK, de Wilt JH, van Der K, et al. Isolated limb perfusion for local gene delivery: efficient and targeted adenovirus-mediated gene transfer into soft tissue sarcomas. Ann Surg 2000;232:814-21.
17. de Wilt JH, Bout A, Eggermont AM, et al. Adenovirus-mediated interleukin 3 beta gene transfer by isolated limb perfusion inhibits growth of limb sarcoma in rats. Hum Gene Ther 2001;12:489-502.
18. Manusama ER, de Wilt JH, ten Hagen TL, Marquet RL, Eggermont AM. Toxicity and antitumor activity of interferon gamma alone and in combinations with TNFalpha and melphalan in isolated limb perfusion in the BN175 sarcoma tumor model in rats. Oncol Rep 1999;6:173-7.